Mithramycin A Workflows for Cancer Research
2026-08-31
Mithramycin A combines G-C-rich DNA recognition with transcription-focused assay design, making it useful for c-myc studies, myeloid differentiation experiments, and promoter-level mechanistic work. This guide translates its chemistry into practical workflows while showing how findings from a doxorubicin-induced heart-failure study can inform—not replace—cancer biology experiments.
U 46619 in Platelet and Vascular Research
2026-08-30
U 46619 provides a controllable TP-receptor stimulus for separating platelet shape change, signaling, serotonin release, aggregation, and vascular tone. This guide translates its concentration-dependent biology into practical assay workflows, endpoint selection, and troubleshooting strategies for cardiovascular and renal research.
Sulfamonomethoxine: From Use to Environmental Fate
2026-08-29
Sulfamonomethoxine (SMM) is examined through a decision-focused framework linking DHPS inhibition, veterinary and aquaculture use, assay formulation, and environmental transformation. Drawing on aerobic granular sludge research, this guide shows how to distinguish adsorption from biodegradation and interpret aquatic toxicity responsibly.
Psora 4: Kv1.3 Blocker Workflows
2026-08-29
Psora 4 enables mechanism-focused studies of Kv1.3-dependent T-cell signaling, from acute calcium imaging to effector-memory proliferation assays. Its value is greatest when concentration, solvent, cell phenotype, and KCNE4-dependent channel architecture are controlled together.
CSBTA Pharmacokinetics in MASH: Key Study Insights
2026-08-28
A 2025 study integrated pharmacokinetic, tissue-distribution, transport, and metabolism data to show how HFHCD-induced MASH changes the disposition of Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic exposure, hepatic distribution, and hepatocyte accumulation through coordinated changes in CYP450 enzymes and transporters regulated in part through PXR.
ROS-Driven Metabolic Rewiring in Melanoma
2026-08-28
Cesi et al. show that BRAF or MEK pathway inhibition increases reactive oxygen species, activates pyruvate dehydrogenase kinases, and phosphorylates PDH-E1α in melanoma cells. The study identifies PDK inhibition as a potential metabolic vulnerability, including in BRAF inhibitor-resistant models, while highlighting the need to control metabolic variables in cell-culture experiments.
JHU-083: From Glutaminase to Neuro-Redox Assays
2026-08-27
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase perturbation in cerebral CD11b cells. This article explains how to use it as a mechanistic tool for experimental cerebral malaria research and neuro-redox assay design while avoiding unsupported conclusions from hepatic toxicity studies.
Dutasteride Assays: From DHT Biology to Causal Design
2026-08-27
Dutasteride is a dual 5-alpha-reductase inhibitor for dissecting testosterone-to-DHT signaling in prostate models. This guide introduces a causal, compartment-aware assay strategy inspired by recent hepatocyte–macrophage research without overstating cross-domain evidence.
Cefazedone (Refosporen): Applied Lab Workflows
2026-08-26
Cefazedone (Refosporen) supports reproducible broth-dilution, susceptibility, time-kill, and translational PK/PD workflows spanning Gram-positive and Gram-negative bacterial infections. This practical guide connects solvent handling and MIC determination with the time-dependent exposure findings reported in community-acquired pneumonia.
Capillarisenol C and ER Stress-Driven Autophagic Death
2026-08-26
The reference study identifies capillarisenol C, a bisphenol from Artemisia capillaris, as an inducer of ER stress-associated cytotoxic autophagy in HepG2 and Huh7 liver cancer cells. Its use of apoptosis inhibition, autophagy perturbation, ER stress markers, and 4-PBA rescue provides a useful framework for distinguishing autophagic cell death from nonspecific cytotoxicity.
Targeting GDH in HSCs to Alleviate Liver Fibrosis
2026-08-25
The reference study identifies glutamine catabolism in hepatic stellate cells as a therapeutically relevant metabolic dependency in liver fibrosis. Its central innovation is linking reduced SIRT4 expression to increased GDH activity, α-ketoglutarate production, and HSC proliferation, while showing that both EGCG treatment and SIRT4 overexpression can restrain fibrotic progression.
ML385 for Reproducible NRF2 Assays
2026-08-25
This scenario-based guide explains how ML385 (SKU B8300) can be incorporated into cell viability, cytotoxicity, oxidative-stress, and therapeutic-resistance experiments. It connects product specifications with practical controls for dosing, solvent management, interpretation, and vendor selection.
Tunicamycin: N-Glycosylation Inhibitor for ER Stress
2026-08-24
Tunicamycin is a potent N-glycosylation inhibitor and an endoplasmic reticulum stress inducer used to dissect glycoprotein synthesis, UPR signaling, and inflammatory responses. Its strongest research value is mechanistic: it creates an upstream glycosylation blockade that can be measured through GRP78, ATF6, inflammatory mediators, viability, and pathway-specific controls.
Batimastat (BB-94): Reliable Cell Assays
2026-08-23
This scenario-driven guide explains how Batimastat (BB-94), SKU A2577, can improve interpretation of cell viability, proliferation, cytotoxicity, and MMP-related experiments. It covers mechanism, solvent controls, storage, dose interpretation, tumor models, and practical vendor-selection criteria.
GSK-923295 for Reproducible Mitotic Assays
2026-08-22
This scenario-driven guide explains how GSK-923295 (SKU A3450) can support mechanistic cell-cycle, viability, proliferation, and cytotoxicity studies through defined CENP-E inhibition. It covers formulation, assay compatibility, protocol optimization, data interpretation, and practical vendor-selection criteria for cancer research.
464 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page